Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Use This to Evaluate MRD Prior to Allo-SCT

Leuk Res; 2017 Dec; Candoni, De Marchi, et al

Publish date:: November 19, 2017

Using Wilms' tumor expression to evaluate minimal residual disease prior to allogeneic stem cell transplantation (allo-SCT) can help predict post-transplant outcomes in patients with acute myeloid leukemia (AML) in cytologic complete remission, according to a study involving 122 individuals. Participants included patients with AML who were MRD-WT1 negative (n=81) or positive (n=41). Investigators looked at post-SCT overall survival, disease free survival, and relapse rate. Among the results:

Post-allo-SCT overall and disease-free survival rates were significantly better in patients who were MRD-WT1 negative at the time of SCT, vs those who were positive.
Both overall and disease-free survival were not reached in the negative group; in the positive group, they were 9 and 8 months, respectively.
Relapse rate post-SCT was 15% and 44%, respectively.
MRD-WT1 negativity pre-SCT and grade <2 acute graft-versus-host disease significantly predicted improved overall and disease-free survival, according to univariate analysis.
MRD-WT1 negativity pre-SCT was the only independent prognostic factor for improved overall and disease-free survival, according to multivariate analysis.

Citation:

Candoni A, De Marchi F, Zannier, ME. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission. Leuk Res. 2017;63:22-27. doi:10.1016/j.leukres.2017.10.010.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in AML

Azacitidine in Lower-Risk MDS Shows Promise, Oncologist; ePub 2017 Nov 8; Komrokji, et al

Clostridium Difficile Infection in People with MDS, World J Clin Oncol; 2017 Oct 10; Shaht, et al

Survival in Azacitidine-Treated Patients Assessed, Leuk Res; 2017 Oct 27; Sébert, Komrokji et al

Use This to Evaluate MRD Prior to Allo-SCT, Leuk Res; 2017 Dec; Candoni, De Marchi, et al

Detecting Minimal Residual Disease in AML, Curr Hematol Malig Rep; ePub 2017 Nov 2; Zhou, et al